Based on the information available, Aurobindo Pharma, a pharmaceutical company, has implemented various safety measures for their workers during the production of Clonazepam and other drugs. However, the specific details of these measures for Clonazepam production are not publicly available.

Aurobindo Pharma has received several observations and warnings from the US Food and Drug Administration (FDA) regarding issues such as inadequate validation, data integrity, and insufficient worker training [1]. In response to these observations, the company has taken corrective actions, which may include implementing or enhancing worker safety measures.

Moreover, Aurobindo Pharma has a policy on "Health, Safety and Environment" that covers employee health and safety [2]. The policy mentions the company's commitment to providing a safe and healthy work environment and adhering to regulations.

DrugPatentWatch.com, a website that tracks drug patents and pharmaceutical companies, does not provide specific information on worker safety measures during Clonazepam production at Aurobindo Pharma [3].

In conclusion, while there is information available on Aurobindo Pharma's commitment to worker safety and corrective actions taken in response to FDA observations, specific details on worker safety measures during Clonazepam production are not publicly available.

Sources:

1. US Food and Drug Administration. (2021). Inspectional Observations - Form FDA 483. <https://www.accessdata.fda.gov/scripts/inspections/acceldocs/inspection_docs/2021/P022512S009-Insp-01-Observations.pdf>
2. Aurobindo Pharma. (n.d.). Health, Safety and Environment Policy. <https://www.aurobindo.com/sustainability/policies/HSE-Policy.pdf>
3. DrugPatentWatch. (n.d.). Aurobindo Pharma. <https://www.drugpatentwatch.com/aurbindo-pharma/>